<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9E44DE61-7B66-41DA-A507-76FD16A1DC76"><gtr:id>9E44DE61-7B66-41DA-A507-76FD16A1DC76</gtr:id><gtr:name>European Developing Countries</gtr:name><gtr:address><gtr:line1>Laan van Nieuw Oost Indie 334</gtr:line1><gtr:postCode>2509 AA</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E44DE61-7B66-41DA-A507-76FD16A1DC76"><gtr:id>9E44DE61-7B66-41DA-A507-76FD16A1DC76</gtr:id><gtr:name>European Developing Countries</gtr:name><gtr:address><gtr:line1>Laan van Nieuw Oost Indie 334</gtr:line1><gtr:postCode>2509 AA</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles/><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15003"><gtr:id>32397611-A1B7-4629-A44A-C2DABC4EDBC5</gtr:id><gtr:title>European &amp;amp; Developing Countries Clinical Trials Partnership</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15003</gtr:grantReference><gtr:abstractText>EDCTP is a public-public partnership between countries in Europe, sub-Saharan Africa and the European Union. The countries currently participating in EDCTP as members of the EDCTP Association are:
14 European countries ? Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, UK; and
14 African countries ? Burkina Faso, Cameroon, Congo, Gabon, The Gambia, Ghana, Mali, Mozambique, Niger, Senegal, South Africa, Tanzania, Uganda and Zambia.
MRC contributes annually to this funding partnership to support EDCTP research and capacity building activities. 
All EDCTP-funded projects are undertaken in partnership with sub-Saharan countries. 
EDCTP aims to support collaborative research that accelerates the clinical development of new or improved medical interventions to prevent or treat HIV/AIDS, tuberculosis, malaria and neglected infectious diseases in sub-Saharan Africa.
EDCTP includes the following neglected infectious diseases: dengue; rabies; human African trypanosomiasis (sleeping sickness); Leishmaniases; cysticercosis/ taeniasis; dracunculiasis (guinea-worm disease); echinococcosis; foodborne trematodiases; lymphatic filariasis; onchocerciasis (river blindness); schistosomiasis; soil-transmitted helminthiases; Buruli ulcer; leprosy (Hansen disease); trachoma; yaws; diarrhoeal infections; lower respiratory infections; as well as emerging infectious diseases of particular relevance for Africa, such as Ebola. 
The programme supports clinical trials and related research activities on PRDs, as well as capacity development for clinical trials and related research in sub-Saharan Africa. EDCTP2 supports all phases of clinical trials (phases I to IV) for new or improved medical interventions, as well as advanced testing and field validation of new diagnostic tools.
Further information can be found on the EDCTP website: http://www.edctp.org/</gtr:abstractText><gtr:technicalSummary>EDCTP is a public-public partnership between countries in Europe, sub-Saharan Africa and the European Union. The countries currently participating in EDCTP as members of the EDCTP Association are:
14 European countries ? Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, UK; and
14 African countries ? Burkina Faso, Cameroon, Congo, Gabon, The Gambia, Ghana, Mali, Mozambique, Niger, Senegal, South Africa, Tanzania, Uganda and Zambia.
MRC contributes annually to this funding partnership to support EDCTP research and capacity building activities. 
All EDCTP-funded projects are undertaken in partnership with sub-Saharan countries. 
EDCTP aims to support collaborative research that accelerates the clinical development of new or improved medical interventions to prevent or treat HIV/AIDS, tuberculosis, malaria and neglected infectious diseases in sub-Saharan Africa.
EDCTP includes the following neglected infectious diseases: dengue; rabies; human African trypanosomiasis (sleeping sickness); Leishmaniases; cysticercosis/ taeniasis; dracunculiasis (guinea-worm disease); echinococcosis; foodborne trematodiases; lymphatic filariasis; onchocerciasis (river blindness); schistosomiasis; soil-transmitted helminthiases; Buruli ulcer; leprosy (Hansen disease); trachoma; yaws; diarrhoeal infections; lower respiratory infections; as well as emerging infectious diseases of particular relevance for Africa, such as Ebola. 
The programme supports clinical trials and related research activities on PRDs, as well as capacity development for clinical trials and related research in sub-Saharan Africa. EDCTP2 supports all phases of clinical trials (phases I to IV) for new or improved medical interventions, as well as advanced testing and field validation of new diagnostic tools.
Further information can be found on the EDCTP website: http://www.edctp.org/</gtr:technicalSummary><gtr:fund><gtr:end>2021-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-12-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>14000000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15003</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>4F7FE31F-D266-4FE9-9BAB-3D21E9B789BA</gtr:id><gtr:percentage>10</gtr:percentage><gtr:text>3.3  Nutrition and chemoprevention</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CCD4E5D4-D30B-4BCF-9FE1-D8BFC3DD43D3</gtr:id><gtr:percentage>10</gtr:percentage><gtr:text>8.3  Policy, ethics and research governance</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>